000			02052nam a22003017a 4500
008			170710s20172017 xxu||||| |||| 00| 0 eng d
022			_a1570-1611
040			_aOvid MEDLINE(R)
099			_a28676024
245			_aNAFLD-NASH: an under-recognized epidemic.
251			_aCurrent Vascular Pharmacology. , 2017 Jun 20
252			_aCurr Vasc Pharmacol. , 2017 Jun 20
253			_aCurrent vascular pharmacology
260			_c2017
260			_fFY2017
266			_d2017-07-10
520			_aCopyright© Bentham Science Publishers; For any queries, please email at [email protected].
520			_aFirst described in 1980, nonalcoholic fatty liver disease (NAFLD) has become more common although the exact incidence and prevalence is unknown. While the exact prevalence varies from region to region, the overall trend shows an increased number of patients with NAFLD. Risk factors for the development of NAFLD includes advanced age, male gender, obesity, and having elements of the metabolic syndrome. There is also an association between the presence of NAFLD and coronary atherosclerosis. Persons of Hispanic descent tend to have higher rates of NAFLD when compared with other populations. Genetics, specifically polymorphisms in the gene PNPLA3, may explain the difference among these different groups. As the rates of obesity increases throughout the world, it is anticipated that the rate of NAFLD will continue to increase. This has large scale implications on the rates of cirrhosis, hepatocellular carcinoma, liver transplantation and cardiovascular events that could impact hundreds of millions of people.
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
651			_aMedStar Washington Hospital Center
656			_aGastroenterology/Hepatology
657			_aJournal Article
700			_aJennings, Joseph
790			_aFaselis C, Jennings J, Yao MD
856			_uhttps://dx.doi.org/10.2174/1570161115666170622074007 _zhttps://dx.doi.org/10.2174/1570161115666170622074007
942			_cART _dArticle
999			_c2477 _d2477